BioSpace News Archive

UroGen Pharma Ltd. today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).

The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals (NASDAQ: AMLX) today announced they are partnering on a real‐world evidence generation initiative for Amylyx’ novel investigational therapy AMX0035.

Kriya Therapeutics, Inc. announced today that it has appointed Ma’an Muhsin, M.D., as President and Chief Medical Officer of Kriya Oncology.

Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol ® Cyclo™ in Niemann-Pick Disease.

Seagen Inc. (Nasdaq:SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival.

Neuropeak Pro, a Precision Breathing, Heart Rate Variability (HRV) and brain performance company that trains elite athletes to enhance performance under pressure, introduced today the first-of-its-kind mobile, real-time precision breathing training device and performance app designed to unlock optimum performance.

BioCardia®, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure.

Kiromic BioPharma, Inc. today announces the appointment of two outside directors to the Company’s Board of Directors: Frank Tirelli and Karen Reeves, M.D.

Ermium Therapeutics is announcing today the establishment of a scientific advisory board.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.